Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PC-535
- Development stage
- Unknown
- Lead developer
- Population Council
- Administration
- Topical, Vaginal
01
Overview
PC-535 is a carrageenan-based vaginal gel developed by the Population Council to serve as a matching placebo control in clinical trials for microbicides, specifically for the Griffithsin-based gel PC-6500. It is designed to match the active formulation in appearance, viscosity, and composition, excluding the active pharmaceutical ingredient (griffithsin). While carrageenan itself has been studied for potential antiviral properties, in this context, PC-535 functions as an inert control to evaluate the safety, pharmacokinetics, and pharmacodynamics of investigational HIV pre-exposure prophylaxis (PrEP) products in healthy women.
Beyond the preview
Go deeper on PC-535.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PC-535.